Skip to main content

Advertisement

SpringerLink
Log in

Albumin nanoparticles coated with polysorbate 80 for the targeted delivery of antiepileptic drug levetiracetam into the brain

  • Original Article
  • Published:
Drug Delivery and Translational Research Aims and scope Submit manuscript

Abstract

The aim of the study was to target levetiracetam (LEV) into the brain by albumin nanoparticles. The levetiracetam-loaded albumin nanoparticles (LEV-NPs) were formulated by desolvation. The particle size of LEV-NPs was 153.7 ± 44.8 nm and the zeta potential was − 10.8 mV. The in vitro LEV release, in pH 6.8 phosphate buffer, was determined by dialysis and showed a biphasic pattern of drug release and ranged in between 40.42 ± 2.6% w/w and 63.61 ± 2.12% w/w. The biodistribution study was conducted on male Wistar rats. The LEV was given as i.v. injection in tail vein, and the formulations were the free drug, LEV-NPs, and levetiracetam-loaded albumin nanoparticles further coated with 1% polysorbate 80 (LEV-NPs-PS 80). A significant increase in LEV concentration was achieved in the brain for LEV-NPs-PS 80 when compared with LEV free drug. The LEV concentration achieved in the brain after administering free drug and LEV-NPs-PS 80 was 5.28 ± 1.79 and 18.54 ± 2.38 μg/gm respectively. The LEV-NPs-PS 80 enhanced LEV concentration in the brain by 3.51-fold when compared with the free drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rao VR, Lowenstein DH. Epilepsy. Curr Biol. 2015;25:R742–6.

    Article  CAS  Google Scholar 

  2. https://www.who.int/news-room/fact-sheets/detail/epilepsy. Accessed 18 Mar 2019.

  3. Leppik IE. Issues in the treatment of epilepsy. Epilepsia. 2001;42(Suppli. 4):1–6.

    Article  Google Scholar 

  4. Klitgaard H, Matagne A, Gobert J, Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191–206.

    Article  CAS  Google Scholar 

  5. Loscher W, Honack D. Profile of UCB L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147–58.

    Article  CAS  Google Scholar 

  6. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47:1128–35.

    Article  CAS  Google Scholar 

  7. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA. 2004;101:9861–6.

    Article  CAS  Google Scholar 

  8. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;4:707–24.

    Article  Google Scholar 

  9. Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatric Dis Treat. 2009;5:467–76.

    CAS  Google Scholar 

  10. Wilson B. Drug targeting strategies into the brain for treating neurological diseases. J Neurosci Methods. 2019;311:133–46.

    Article  Google Scholar 

  11. Muthu MS, Rawat MK, Mishra A, Singh S. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomed Nanotech Biol Med. 2009;5:323–33.

    Article  CAS  Google Scholar 

  12. Wilson B, Lavanya Y, Priyadarshini SRB, Ramasamy M, Jenita JJJ. Albumin nanoparticles for the delivery of gabapentin: preparation, characterization and pharmacodynamic studies. Int J Pharm. 2014;473:73–9.

    Article  CAS  PubMed Central  Google Scholar 

  13. Wilson B, Geetha KM. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Nanomedicine (Lond.). 2020;15:433–6.

    Article  CAS  Google Scholar 

  14. Damascelli B, Cantu G, Mattavelli F, Tamplenizza P, Bidoli E, Leo F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel incorporated in albumin nanoparticles (ABI-007): phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer. 2001;92:2592–602.

    Article  CAS  PubMed Central  Google Scholar 

  15. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles. J Control Release. 1997;49:81–7.

    Article  CAS  Google Scholar 

  16. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm. 2000;49:103–9.

    Article  CAS  PubMed Central  Google Scholar 

  17. Weber C, Kreuter J, Langer K. Desolvation process and surface characteristics of HAS-nanoparticles. Int J Pharm. 2000;196:197–200.

    Article  CAS  PubMed Central  Google Scholar 

  18. Wilson B, Ambika TV, Dharmeshkumar P, Jenita JJL, Priyadarshini SRB. Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery. Int J Biol Macromol. 2012;51:84–8.

    Article  Google Scholar 

  19. Wilson B, Samanta MK, Suresh B. Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer’s disease. Ther Deliv. 2011;2:599–609.

    Article  CAS  PubMed Central  Google Scholar 

  20. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that Polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanism requiring prior binding of drugs to the nanoparticles. Pharm Res. 2003;20:409–16.

    Article  CAS  Google Scholar 

  21. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Ramasamy M, Suresh B. Chitosan nanoparticles as a novel delivery system for anti-Alzheimer’s drug tacrine. Nanomed Nanotech Biol Med. 2010;6:144–52.

    Article  CAS  Google Scholar 

  22. Löbenberg R, Araujo L, von Brisen H, Rodgers E, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release. 1998;50:21–30.

    Article  Google Scholar 

  23. Jun JY, Nguyen HH, Paik SYR, Chun HS, Kang BC, Ko S. Preparation of size-controlled bovine serum albumin (BSA) nanoparticles by a modified desolvation method. Food Chem. 2011;127:1892–8.

    Article  CAS  Google Scholar 

  24. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur J Pharm Biopharm. 2010;74:157–63.

    Article  CAS  Google Scholar 

  25. Tian X-T, Lin X-N, Wei F, Feng W, Huang Z-C, Wang P, et al. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J Nanomed. 2011;6:445–52.

    CAS  Google Scholar 

  26. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159–68.

    Article  CAS  Google Scholar 

  27. Chiannilkulchai N, Ammoury N, Caillou B, Devissageut J, Couvreur P. Hepatic tissue distribution of doxorubicin loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastases-bearing mice. Cancer Chemother Pharmacol. 1990;26:122–6.

    Article  CAS  Google Scholar 

  28. Kwan P, Schachter SC, Brodiem MJ. Drug resistant epilepsy. N Eng J Med. 2011;365:919–26.

    Article  CAS  Google Scholar 

  29. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther. 2002;301:7–14.

    Article  CAS  Google Scholar 

  30. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674:171–4.

    Article  CAS  Google Scholar 

  31. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Pharm Res. 1997;14:325–8.

    Article  CAS  PubMed Central  Google Scholar 

  32. Wilson B, Samanta MK, Santhi K, Sampathkumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2008;70:75–84.

    Article  CAS  PubMed Central  Google Scholar 

  33. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81.

    Article  CAS  PubMed Central  Google Scholar 

  34. Wilson B, Geetha KM. Neurotherapeutic applications of nanomedicine for treating Alzheimer’s disease. J Control Release. 2020;325:25–37.

    Article  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka, 560078, India

    Barnabas Wilson, Janani Selvam & Josephine L. Jenita

  2. Department of Pharmacology, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka, 560078, India

    Geetha K. Mukundan

  3. Department of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Kumaraswamy Layout, Bangalore, Karnataka, 560078, India

    Kudumula B. Premakumari

Authors
  1. Barnabas Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Janani Selvam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geetha K. Mukundan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kudumula B. Premakumari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Josephine L. Jenita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barnabas Wilson.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All institutional and national guidelines for the care and use of laboratory animals were followed.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilson, B., Selvam, J., Mukundan, G.K. et al. Albumin nanoparticles coated with polysorbate 80 for the targeted delivery of antiepileptic drug levetiracetam into the brain. Drug Deliv. and Transl. Res. 10, 1853–1861 (2020). https://doi.org/10.1007/s13346-020-00831-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13346-020-00831-3

Keywords

Search

Navigation